Chemotherapy-induced acral erythema

OnQuality Pharmaceuticals to Present Two Posters at the 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Friday, October 14, 2022

CID is a potentially life-threatening adverse effect of chemotherapy, often requiring dose reduction or disruption of treatment.

Key Points: 
  • CID is a potentially life-threatening adverse effect of chemotherapy, often requiring dose reduction or disruption of treatment.
  • OnQuality is developing OQL051, a gut-restricted CDK4/6 inhibitor with the potential to prevent CID while minimizing interference with systemically administered chemotherapy regimens.
  • The posterat the EORTC-NCI-AACR Symposium will present preclinical toxicology and pharmacology data supporting OQL051's potential as an effective treatment for CID.
  • "We're thrilled to present positive preclinical data for two of our programs that address these unmet needs in cancer therapy," said Robert C. Tyler, Ph.D., Senior Medical Director of OnQuality.

Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting

Retrieved on: 
Wednesday, November 11, 2020

The Company also announced two encore presentations highlighting data from the QINLOCK program, one oral presentation and one poster presentation, which will be featured at the CTOS 2020 Virtual Annual Meeting.

Key Points: 
  • The Company also announced two encore presentations highlighting data from the QINLOCK program, one oral presentation and one poster presentation, which will be featured at the CTOS 2020 Virtual Annual Meeting.
  • QINLOCK also inhibits primary PDGFRA mutations in exons 12, 14, and 18, including the exon 18 D842V mutation, involved in a subset of GIST.
  • Palmar-plantar erythrodysesthesia syndrome (PPES): In INVICTUS, Grade 1-2 PPES occurred in 21% of the 85 patients who received QINLOCK.
  • QINLOCK and the QINLOCK logo are registered trademarks, and Deciphera, Deciphera Pharmaceuticals, and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.

Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020

Retrieved on: 
Friday, September 18, 2020

Deciphera Pharmaceuticals is developing QINLOCK for the treatment of KIT and/or PDGFR-driven cancers, including GIST, SM, and other cancers.

Key Points: 
  • Deciphera Pharmaceuticals is developing QINLOCK for the treatment of KIT and/or PDGFR-driven cancers, including GIST, SM, and other cancers.
  • Palmar-plantar erythrodysesthesia syndrome (PPES): In INVICTUS, Grade 1-2 PPES occurred in 21% of the 85 patients who received QINLOCK.
  • PPES led to dose discontinuation in 1.2% of patients, dose interruption in 2.4% of patients, and dose reduction in 1.2% of patients.
  • Deciphera, Deciphera Pharmaceuticals, QINLOCK, the Deciphera logo and the QINLOCK logo are trademarks of Deciphera Pharmaceuticals, LLC.

Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology

Retrieved on: 
Monday, August 17, 2020

Deciphera Pharmaceuticals is developing QINLOCK for the treatment of KIT and/or PDGFR-driven cancers, including GIST, SM, and other cancers.

Key Points: 
  • Deciphera Pharmaceuticals is developing QINLOCK for the treatment of KIT and/or PDGFR-driven cancers, including GIST, SM, and other cancers.
  • Palmar-plantar erythrodysesthesia syndrome (PPES): In INVICTUS, Grade 1-2 PPES occurred in 21% of the 85 patients who received QINLOCK.
  • PPES led to dose discontinuation in 1.2% of patients, dose interruption in 2.4% of patients, and dose reduction in 1.2% of patients.
  • Deciphera, Deciphera Pharmaceuticals, QINLOCK, the Deciphera logo and the QINLOCK logo are trademarks of Deciphera Pharmaceuticals, LLC.

Deciphera Announces Publication of the INVICTUS Pivotal Phase 3 Study of QINLOCK™ (ripretinib) in The Lancet Oncology

Retrieved on: 
Monday, June 8, 2020

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that The Lancet Oncology has published results from the INVICTUS pivotal Phase 3 study of QINLOCK in patients with fourth-line gastrointestinal stromal tumor (GIST).

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that The Lancet Oncology has published results from the INVICTUS pivotal Phase 3 study of QINLOCK in patients with fourth-line gastrointestinal stromal tumor (GIST).
  • The INVICTUS study met its primary endpoint, demonstrating a statistically significantly improvement in progression free survival (PFS) in patients randomized to QINLOCK compared with patients receiving placebo.
  • Palmar-plantar erythrodysesthesia syndrome (PPES): In INVICTUS, Grade 1-2 PPES occurred in 21% of the 85 patients who received QINLOCK.
  • Deciphera, Deciphera Pharmaceuticals, QINLOCK, the Deciphera logo and the QINLOCK logo are trademarks of Deciphera Pharmaceuticals, LLC.